Report

Our reports provide latest industry trends, forecasts, company profiles, competitive landscape, and strategic insights.

Asset 41 2
160 1608792 circle document icon png transparent png

Australia Lung Cancer Screening Market Forecast to 2030 – Country Analysis by Cancer Type [Non–Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer], Technology [Low-Dose Computed Tomography (LDCT), Chest X-Ray, Liquid Biopsy, and Others], Age Group (50 & Older and Below 50), and End User (Hospitals, Diagnostic Centers, and Others)

The Australia lung cancer screening market size is expected to grow from US$ 2.74 million in 2022 to US$ 6.12 million by 2030; it is estimated to record a CAGR of 10.6% from 2022 to 2030.

The Australia lung cancer screening market growth is attributed to the increasing Incidence of lung cancer and rising government support. However, uncertainties related to lung cancer screening trial with LDCT is hampering the growth of the Australia lung cancer screening market.

Lung cancer screening is a process used to detect lung cancer in otherwise healthy people with a high risk of lung cancer. Lung cancer screening is recommended for older adults who are long time smokers and who don’t have any signs or symptoms of lung cancer. Doctors use a LDCT scan of the lungs to look for lung cancer. If lung cancer is detected early, it’s more likely to be cured with treatment.

Structured Lung Cancer Screening Program is expected to provide the opportunities in the forecast period.

Australia faces unique challenges with lung cancer screening programs. A few examples of population-based Australian screening programs are “BreastScreen,” the “National Bowel Cancer Screening Program,” and the “National Cervical Screening Program.” Therefore, there is a crucial requirement for a well-structured program such as a community-based program or a shared, informed decision-making program between clinicians and potential participants; accredited reporting centers; and a central data registry for quality control, monitoring, and outcome reporting. Additionally, integrated smoking cessation intervention, international data supporting cost-effectiveness, additional mortality benefits, and a high sustainability rate are a few factors that must be studied for lung cancer screening. Further, the International Association for the Study of Lung Cancer (IASLC) recommends implementing feasibility screening programs in the country without participating in lung cancer screening studies. These programs involve smoking cessation initiatives, standardized algorithms for selecting and managing screening participants, and specialist multidisciplinary teams to manage participants with positive screening results. Therefore, the implementation of structured lung cancer screening programs in the country is expected to be a lucrative opportunity in the Australia lung cancer screening market during the forecast period.

Australia Lung Cancer Screening Market – Test Type Insights

Based on cancer type, the Australia lung cancer screening market is bifurcated into NSCLC and small cell lung cancer. The NSCLC segment accounted for the largest market share in 2022 and is expected to grow at a CAGR of 10.3% during the forecast period. The market position of this segment is due to the rising cases of NSCLC in Australia. NSCLC develops more slowly than small cell lung cancer. It usually spreads to other parts of the patient’s body by the time it is diagnosed. Therefore, early diagnosis and treatment are crucial. According to National Foundation for Cancer Research, NSCLC accounts for nearly 9 out of every 10 diagnoses. As per the same source, large-cell undifferentiated carcinoma lung cancer accounts for approximately 10–15% of all NSCLC diagnoses.

Based on technology, the Australia lung cancer screening market is segmented into LDCT, chest X-ray, liquid biopsy, and others. The chest X-ray segment accounted for the largest market share in 2022, however, the LDCT is expected to grow at a CAGR of 11.9% during the forecast period.

Based on age group, the Australia lung cancer screening market is bifurcated into 50 & older and below 50. The 50 & older segment accounted for the largest market share in 2022, however, the below 50 is expected to grow at a CAGR of 11.3% during the forecast period.

Based on end user, the Australia lung cancer screening market is segmented into hospitals, diagnostic centers, and others. The hospitals segment accounted for the largest market share in 2022, however, the others is expected to grow at a CAGR of 11.1% during the forecast period.

Australia Lung Cancer Screening Market – Recent Developments:

Inorganic and organic strategies such as mergers and acquisitions are highly adopted by companies in the Australia lung cancer screening market. A few recent key market developments are listed below:

In June 2022, Royal Philips teamed up with Biodesix, Inc. to incorporate the results of Biodesix’s Nodify Lung blood-based lung nodule risk assessment testing into Philips Lung Cancer Orchestrator lung cancer patient management system. The incorporation of proteomics data along with the radiologic and patient history data currently used to determine treatment decisions can help create diagnostic efficiency for cancer care centers in the management of a growing number of lung nodule cases via the contextual launch of Biodesix Nodify Lung application within Lung Cancer Orchestrator.

In August 2022, Intelerad Medical Systems acquired of PenRad Technologies, Inc., a software provider for enhancing breast imaging and lung screening productivity. The acquisition has expanded Intelerad’s product offerings for mammography and lung analytics, optimizing workflow for radiologists and boosting patient health outcomes.

TABLE OF CONTENTS

1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Australia Lung Cancer Screening Market – by Technology
1.3.2 Australia Lung Cancer Screening Market – by Cancer Type
1.3.3 Australia Lung Cancer Screening Market – by Age Group
1.3.4 Australia Lung Cancer Screening Market – by End User
2. Australia Lung Cancer Screening Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Australia Lung Cancer Screening Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Expert’s Opinion
4.4 Demographics of Smoking, by Key States
4.5 Demographics of Smoking, by Income Bracket
4.6 Epidemiology of Lung Cancer in Australia
4.7 Patterns of Smoking in Australia
4.8 Trends Of Smoking in Australia
4.9 Regional Comparative Analysis of Smoking (Asian and European)
5. Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Incidence of Lung Cancer
5.1.2 Rising Government Support
5.2 Market Restraints
5.2.1 Uncertainties Related to Lung Cancer Screening Trial with LDCT
5.3 Market Opportunities
5.3.1 Structured Lung Cancer Screening Program
5.4 Future Trends
5.4.1 Mobile Lung Cancer Screening Truck
5.5 Impact Analysis
6. Lung Cancer Screening Market – Australia Analysis
6.1 Australia Lung Cancer Screening Market Revenue Forecast and Analysis
7. Australia Lung Cancer Screening Market Analysis – by Cancer Type
7.1 Overview
7.2 Australia Lung Cancer Screening Market, by Cancer Type – Revenue and Forecast to 2030 (US$ Thousand)
7.3 Non–Small Cell Lung Cancer (NSCLC)
7.3.1 Overview
7.3.2 Non–small cell lung cancer (NSCLC): Australia Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Thousand)
7.4 Small Cell Lung Cancer
7.4.1 Overview
7.4.2 Small Cell Lung Cancer: Australia Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Thousand)
8. Australia Lung Cancer Screening Market Analysis – by Technology
8.1 Overview
8.2 Australia Lung Cancer Screening Market, by Technology – Revenue and Forecast to 2030 (US$ Thousand)
8.3 Low-Dose Computed Tomography (LDCT)
8.3.1 Overview
8.3.2 Low-Dose Computed Tomography (LDCT): Lung Cancer Screening Market– Revenue and Forecast to 2030 (US$ Thousand)
8.4 Chest X-ray
8.4.1 Overview
8.4.2 Chest X-ray: Lung Cancer Screening Market– Revenue and Forecast to 2030 (US$ Thousand)
8.5 Liquid Biopsy
8.5.1 Overview
8.5.2 Liquid Biopsy: Lung Cancer Screening Market– Revenue and Forecast to 2030 (US$ Thousand)
8.6 Others
8.6.1 Overview
8.6.2 Others: Lung Cancer Screening Market– Revenue and Forecast to 2030 (US$ Thousand)
9. Australia Lung Cancer Screening Market Analysis – by Age Group
9.1 Overview
9.2 Australia Lung Cancer Screening Market, by Age Group – Revenue and Forecast to 2030 (US$ Thousand)
9.3 & Older
9.3.1 Overview
9.3.2 & Older: Australia Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Thousand)
9.4 Below 50
9.4.1 Overview
9.4.2 Below 50: Australia Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Thousand)
10. Australia Lung Cancer Screening Market Analysis – by End User
10.1 Overview
10.2 Australia Lung Cancer Screening Market, by End User – Revenue and Forecast to 2030 (US$ Thousand)
10.3 Hospitals
10.3.1 Overview
10.3.2 Hospitals: Australia Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Thousand)
10.4 Diagnostic Centers
10.4.1 Overview
10.4.2 Diagnostic Centers: Australia Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Thousand)
10.5 Others
10.5.1 Overview
10.5.2 Others: Australia Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Thousand)
11. Australia Lung Cancer Screening Market: Impact Assessment of COVID-19 Pandemic
11.1 Impact Analysis of COVID-19 Pandemic on Australia Lung Cancer Screening Market
12. Australia Lung Cancer Screening Market–Industry Landscape
12.1 Recent Growth Strategies
12.1.1 Overview
13. Company Profiles
13.1 Intelerad Medical Systems
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Nuance Communications Inc
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 GE HealthCare
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Medtronic
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Canon Inc.
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Koninklijke Philips NV
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Siemens AG
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 CVS Health
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 bioAffinity Technologies, Inc.
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 LungLife AI, Inc.
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
13.11 Lung Screen Australia Pty Ltd
13.11.1 Key Facts
13.11.2 Business Description
13.11.3 Products and Services
13.11.4 Financial Overview
13.11.5 SWOT Analysis
13.11.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms

LIST OF TABLES

Table 1. Australia Lung Cancer Screening Market, by Cancer Type – Revenue and Forecast to 2030 (US$ Thousand)
Table 2. Australia Lung Cancer Screening Market, by Technology – Revenue and Forecast to 2030 (US$ Thousand)
Table 3. Australia Lung Cancer Screening Market, by Age Group – Revenue and Forecast to 2030 (US$ Thousand)
Table 4. Australia Lung Cancer Screening Market, by End User – Revenue and Forecast to 2030 (US$ Thousand)
Table 5. Recent Growth Strategies in the Australia Lung Cancer Screening Market
Table 6. Glossary of Terms

LIST OF FIGURES

Figure 1. Australia Lung Cancer Screening Market Segmentation
Figure 2. Australia Lung Cancer Screening Market Overview
Figure 3. Non-Small Cell Lung Cancer Segment Held Largest Share Under Cancer Type Segment in Australia Lung Cancer Screening Market
Figure 4. Experts’ Opinion
Figure 5. Australia Lung Cancer Screening Market: Impact Analysis of Drivers and Restraints
Figure 6. Australia Lung Cancer Screening Market – Revenue Forecast and Analysis – 2020- 2030
Figure 7. Market Positioning of Key Players in Australia Lung Cancer Screening Market
Figure 8. Australia Lung Cancer Screening Market, by Cancer Type, 2022 & 2030 (%)
Figure 9. Non–Small Cell Lung Cancer (NSCLC): Australia Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Thousand)
Figure 10. Small Cell Lung Cancer: Australia Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Thousand)
Figure 11. Australia Lung Cancer Screening Market, by Technology, 2022 & 2030 (%)
Figure 12. Low-Dose Computed Tomography (LDCT): Lung Cancer Screening Market– Revenue and Forecast to 2030 (US$ Thousand)
Figure 13. Chest X-ray: Lung Cancer Screening Market– Revenue and Forecast to 2030 (US$ Thousand)
Figure 14. Liquid Biopsy: Lung Cancer Screening Market– Revenue and Forecast to 2030 (US$ Thousand)
Figure 15. Others: Lung Cancer Screening Market– Revenue and Forecast to 2030 (US$ Thousand)
Figure 16. Australia Lung Cancer Screening Market, by Age group, 2022 & 2030 (%)
Figure 17. & Older: Australia Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Thousand)
Figure 18. Below 50: Australia Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Thousand)
Figure 19. Australia Lung Cancer Screening Market, by End User, 2022 & 2030 (%)
Figure 20. Hospitals: Australia Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Thousand)
Figure 21. Diagnostic Centers: Australia Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Thousand)
Figure 22. Others: Australia Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Thousand)
Figure 23. Pre and Post COVID-19 Pandemic Impact in the Australia Market

● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Australia lung cancer screening market.
● Highlights key business priorities in order to assist companies to realign their business strategies.
● The key findings and recommendations highlight crucial progressive industry trends in the Australia lung cancer screening market, thereby allowing players across the value chain to develop effective long-term strategies.
● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
● Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
● Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

The List of Companies – Australia Lung Cancer Screenings Market
● Intelerad Medical Systems Incorporated
● Nuance Communications Inc
● GE HealthCare Technologies Inc
● Medtronic Plc
● Canon Medical Systems Corp
● Koninklijke Philips NV
● Siemens AG
● CVS Health
● bioAffinity Technologies, Inc.
● LungLife AI, Inc.
● Lung Screen Australia Pty Ltd

Pricing

$3,000.00$5,000.00

Have a Query?

Have a Question?

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

GET FREE SAMPLE PDF

× Enquire Now